/
Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer

Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer - PowerPoint Presentation

min-jolicoeur
min-jolicoeur . @min-jolicoeur
Follow
355 views
Uploaded On 2018-11-08

Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer - PPT Presentation

This program will include a discussion of offlabel treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form These data should be considered preliminary until published in a peerreviewed journal ID: 722707

inhibitors cdk monaleesa monarch cdk inhibitors monarch monaleesa palbociclib paloma data abemaciclib disease progressive integrating practice letrozole treatment differentiating

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "Differentiating Among the CDK 4/6 Inhibi..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript